Association recommends minimum set of pharmacogenetic alleles to guide clinical CYP2D6 genotype testing
American Academy of Neurology says police must end use of neck restraints
10 June 2021Study identifies how COVID-19 linked to Alzheimer’s disease-like cognitive impairment
10 June 2021Association recommends minimum set of pharmacogenetic alleles to guide clinical CYP2D6 genotype testing
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, has today published consensus recommendations to aid in the design and validation of clinical CYP2D6 assays, promote standardization of testing across different laboratories and improve patient care. The manuscript, “Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy,” was released online ahead of publication in The Journal of Molecular Diagnostics.
